All for Joomla All for Webmasters

Autoantibody profiles in the management of Undifferentiated Connective Tissue Disease (UCTD)

Rate this item
(0 votes)

Questions/answers on Autoantibody profiles in the management of Undifferentiated Connective Tissue Disease (UCTD)

Subjects with clinical and serological features that might be indicative of an autoimmune disorder but not meeting the classification criteria for a defined connective tissue disease can be diagnosed as having UCTD. For subjects with evidence of autoimmunity dysregulation consistent with SLE such as anti-DNA antibodies but with no clinical features of the disease the nomenclature of “pre-clinical-SLE” has been proposed.

To be classified as having UCTD, subjects should present with both clinical and serological features that might be indicative of an autoimmune disorder but not meeting the classification criteria for a defined connective tissue disease. In selected subjects with suggestive clinical manifestations, ANA positivity, even in the absence of ENA, can support the diagnosis of UCTD.

The patho-physiological importance of DFS70 specificity is not fully understood yet. The presence of anti-​DFS70 antibodies has been proposed as a possible explanation for the finding of a high-​titre ANA test result for some subjects with no evidence of an ANA- ​associated rheumatic disease. From this perspective, it has been suggested that the presence of monospecific anti-​DFS70 antibodies (that is, anti-​DFS70 in the absence of a disease-​associated antibody) can be used as a biomarker to identify individuals without an ANA-​associated rheumatic disease. However, from a clinical point of view, it has been argued that the absence of disease-​associated ANAs and clinical symptoms should contribute to the exclusion of an ANA-associated rheumatic disease, including UCTD, rather than the sole presence of anti-DFS70 antibodies.

A growing body of evidence is supporting the role of aPL as risk factors for thrombosis and pregnancy morbidity, suggesting the concept that higher the number of aPL positive tests, higher the risk. aPL profile should guide both primary and secondary thrombo- prophylaxis in order to reduce the risk of first or recurrent events, respectively. Ideally, aPL profiling should influence the design of future clinical trials in the field.

Additional Info

Read 2829 times

Werfen.com. All rights Reserved. Privacy Policy | Cookies Policy | Terms of Service

No Internet Connection